Irinotecan, Temozolomide and Bevacizumab in Combination With Existing High Dose Alkylator Based Chemotherapy for Treatment of Newly Diagnosed Patients With Desmoplastic Small Round Cell Tumor | MicrobiomeTrials
Irinotecan, Temozolomide and Bevacizumab in Combination With Existing High Dose Alkylator Based Chemotherapy for Treatment of Newly Diagnosed Patients With Desmoplastic Small Round Cell Tumor
RecruitingEARLY_PHASE1INTERVENTIONAL
Trial Details
Start: 2010-08Est. Completion: 2027-08
Enrollment target: 15 participants
Locations
Memorial Sloan Kettering Cancer Center, New York, New York, United States
Other microbiome trials you might be interested in